Mictonetten (Propiverine Hydrochloride)

Propiverine hydrochloride blocks muscarinic receptors (mainly M2 and M3) in the bladder’s detrusor muscle, decreasing acetylcholine‑mediated contractions. This action lowers involuntary bladder activity, thereby reducing urgency, frequency, and episodes of incontinence.

The specific dose of Mictonetten is determined by the prescribing healthcare professional based on the individual’s condition, age, renal and hepatic function, and response to therapy. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety data for propiverine hydrochloride in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their healthcare provider.

To order Mictonetten, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Mictonetten (propiverine) belongs to the antimuscarinic class, similar to oxybutynin and tolterodine. Compared with some alternatives, propiverine may have a longer duration of action and a different side‑effect profile, but individual response varies. Clinicians choose therapy based on efficacy, tolerability, comorbidities, and patient preference.

Mictonetten should be stored at ambient temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and do not store in bathrooms or other humid environments.

Mictonetten is taken orally, usually once daily, with or without food, as directed by the prescribing physician. Swallow the tablet whole with a glass of water; do not crush or chew unless specifically instructed.

Serious risks include urinary retention, which can lead to bladder over‑distension, and severe allergic reactions such as rash, angioedema, or anaphylaxis. Patients should seek immediate medical attention if they experience difficulty urinating, swelling, or signs of a severe allergic response.

Mictonetten is contraindicated in patients with narrow‑angle glaucoma, severe urinary retention, or known hypersensitivity to propiverine or other antimuscarinic agents. Caution is also advised for individuals with significant renal or hepatic impairment, and it should be avoided in pregnant or breastfeeding women unless clearly indicated.